ArticlemBio2019
Modified Antibiotic Adjuvant Ratios Can Slow and Steer the Evolution of Resistance: Co-amoxiclav as a Case Study.
Article in mBio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Berberine Interferes with the Molecular Landscape of Biofilm-Driven Pathogenicity.Pathogens (Basel, Switzerland) · 2026Review
- Old drugs, new weapons: current trends in repurposing therapies against antimicrobial resistance.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026Review
- A Comprehensive Overview of Antibacterial Agents for Combating Multidrug-Resistant Bacteria: The Current Landscape, Development, Future Opportunities, and Challenges.Antibiotics (Basel, Switzerland) · 2025Review
- Private benefit of β-lactamase dictates selection dynamics of combination antibiotic treatment.Nature communications · 2024Article
- Synthesis, Stereochemical Resolution, and Analogue Synthesis of Variabiline, an Aporphine Alkaloid That SensitizesACS infectious diseases · 2024Article
- The synergistic antibacterial activity and mechanism of colistin-oxethazaine combination against gram-negative pathogens.Frontiers in pharmacology · 2024Article
- Bacterial resistance to antibacterial agents: Mechanisms, control strategies, and implications for global health.The Science of the total environment · 2023Review
- Mechanism of Action of Isopropoxy Benzene Guanidine against Multidrug-Resistant Pathogens.Microbiology spectrum · 2023Article
- Draft genome sequence ofAccess microbiology · 2023Article
- Antibiotic adjuvants: synergistic tool to combat multi-drug resistant pathogens.Frontiers in cellular and infection microbiology · 2023Review
- Restoring and Enhancing the Potency of Existing Antibiotics against Drug-Resistant Gram-Negative Bacteria through the Development of Potent Small-Molecule Adjuvants.ACS infectious diseases · 2022Article
- Increased copy number couples the evolution of plasmid horizontal transmission and plasmid-encoded antibiotic resistance.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- A broad-spectrum antibiotic adjuvant reverses multidrug-resistant Gram-negative pathogens.Nature microbiology · 2020Article
- Effect of new carbonyl cyanide aromatic hydrazones on biofilm inhibition against methicillin resistantRSC advances · 2020Article
- Steering Phages to Combat Bacterial Pathogens.Trends in microbiology · 2020Review
- Applying ecological resistance and resilience to dissect bacterial antibiotic responses.Science advances · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As antibiotic resistance spreads, developing sustainable methods to restore the efficacy of existing antibiotics is increasingly important. One widespread method is to combine antibiotics with synergistically acting adjuvants that inhibit resistance mechanisms, allowing drug killing. Here we use co-amoxiclav (a clinically important combination of the β-lactam antibiotic amoxicillin and the β-lactamase inhibitor clavulanate) to ask whether treatment efficacy and resistance evolution can be decoupled via component dosing modifications. A simple mathematical model predicts that different ratios of these two drug components can produce distinct evolutionary responses irrespective of the initial efficacy. We test this hypothesis by selecting
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.